Skip to main content

Table 1 Correlations of PD-L2 methylation with mRNA expression, lymphocyte score, and overall survival

From: Prognostic and predictive value of PD-L2 DNA methylation and mRNA expression in melanoma

 Methylation or mRNA expressionCorrelation with mRNA expressionCorrelation with lymphocyte scoreOverall survival (Cox proportional hazards)
AnalyteMean (95% confidence interval)Spearman’s ρP valueSpearman’s ρP valueHazard ratio (95% CI)P value
PD-L2 mRNA94 (79–108)NANA0.49< 0.0010.85 (0.77–0.94)0.001
cg1444066472.0 (70.6–73.5)0.110.0180.100.0780.63 (0.44–0.90)0.012
cg0721125925.6 (23.6–27.5)− 0.43< 0.001− 0.22< 0.0011.16 (1.02–1.33)0.027
cg1435195280.0 (78.8–81.1)0.23< 0.001− 0.020.780.58 (0.36–0.92)0.021
cg1413306451.8 (50.1–53.5)− 0.18< 0.001− 0.27< 0.0010.84 (0.63–1.12)0.24
cg1437499486.6 (85.9–87.3)0.32< 0.0010.050.400.30 (0.10–0.86)0.025
  1. PD-L2 methylation was determined at five different CpG sites each gene targeted by HumanMethylation450 BeadChip beads (Fig. 1). PD-L2 methylation and mRNA expression were analyzed as log2-transformed variable. Significant features are shown in boldface.
  2. Correlations were performed including N = 468 (PD-L2 methylation and mRNA expression), N = 328 (lymphocyte score and PD-L2 mRNA expression), N = 329 (lymphocyte score and PD-L2 methylation) samples.